Antibiotic therapy for fever with low white blood cells in blood cancer
Part of Blood & lymphatic clinical trials.
This trial tests whether an antibiotic called ceftazidime-avibactam (CAZ-AVI) can help patients with blood cancers who have a fever and very low infection-fighting white blood cells. It may be an option for people whose doctors plan to use this specific antibiotic to treat their fever.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 75 years old.
- You must have a blood cancer like leukemia, lymphoma, multiple myeloma, or severe aplastic anemia.
- Your infection-fighting white cells (neutrophils) must be very low at the start of the study or expected to drop soon.
- You must have a fever (temperature at least 100.9°F by mouth, or 100.4°F under the arm for over an hour).
- You must be able to take care of yourself (ECOG score 0-2).
- Your doctor must be planning to treat your fever with a specific antibiotic called ceftazidime-avibactam.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether adults with “high-risk febrile neutropenia” can safely get a shorter course of antibiotics. It may help reduce side effects from antibiotics while still keeping infections under control.
This trial studies whether proteins in your blood can predict complications when you have a fever and very low white blood cells after cancer treatment. It aims to help doctors choose the best antibiotics early on.
This study tests whether it's safe to stop antibiotics early in patients who have had a fever while their immune system is weak from chemotherapy. If you've been fever-free for 48 hours, you may be able to avoid unnecessary antibiotics.
This trial tests whether adding a medicine called G-CSF (which helps your body make more white blood cells) to standard antibiotics works better than antibiotics alone for children with fever and low white blood cells caused by cancer treatment.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
This trial compares two antibiotics, ciprofloxacin and ceftazidime, to see which works better for treating fever in children with blood cancer who have a high risk of infection due to low white blood cells. The goal is to find the best treatment to help your child recover faster.
Hear when a new Febrile Neutropenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.